1. Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience. (November 2022) Authors: Caldart, A.; Fiorio, E.; Zanelli, S.; Biondani, P.; Parolin, V.; Pellini, F.; Montemezzi, S.; Nottegar, A.; Caliò, A.; Zampiva, I.; Merler, S.; Mongillo, M.; Avesani, B.; Borghesani, G.; Giontella, E.; Scarpa, A.; Milella, M. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗